A process is provided for preparing dronedarone or pharmaceutically acceptable salts thereof. The process comprises reacting 5-amino-2-butyl-3-(4-[3-(dibutylamino)propoxy]benzoyl)benzofuran (compound A) with methanesulfonyl chloride without any catalyst to provide crude dronedarone hydrochloride, which is purified to afford highly pure product. Then, the dronedarone hydrochloride can be converted to highly pure dronedarone through treatment with an alkaline solvent, the dronedarone can be further converted to other pharmaceutically acceptable salts of dronedarone. In this process, acylation between compound A and methanesulfonyl chloride is carried out successfully and the formation of the dimethylsulfonyl by-product is inhibited.
本发明提供了一种制备多瑞纳酮或其药学上可接受的盐的方法。该方法包括将5-
氨基-2-丁基-3-(4-[3-(二丁基
氨基)丙氧基]苯甲酰)
苯并呋喃(化合物A)与甲
磺酰氯反应,不需要催化剂,以提供粗多瑞纳酮盐酸盐,然后对其进行纯化以得到高度纯净的产物。然后,多瑞纳酮盐酸盐可以通过与碱性溶剂处理转化为高度纯净的多瑞纳酮,多瑞纳酮可以进一步转化为其他药学上可接受的多瑞纳酮盐。在此过程中,化合物A和甲
磺酰氯之间的酰化反应成功进行,并抑制了二甲基磺酰副产物的形成。